NASDAQ · Biotechnology

ARTV (ARTV) Stock

$11.27 -2.68% NASDAQ: ARTV Healthcare

Valuation

MetricValue
Price$11.27
Market Cap$278.56M
P/E Ratio-2.29
P/B Ratio1.77
P/S Ratio0.00
EPS (TTM)$0.00
52-Week High$14.53
52-Week Low$1.47
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-76.36%
ROA-64.12%
ROCE-82.73%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.12
Current Ratio8.69

Annual Financials (USD)

Metric20212022202320242025
Revenue$2.0M$5.0M$33.0M$0$0
Operating Profit$-53.0M$-60.0M$-31.0M$-67.0M$-91.0M
Net Profit$-72.0M$-58.0M$-28.0M$-58.0M$-84.0M
EPS$-4.08$-3.32$-1.19$-5.20$-3.43
Op Margin-2660.9%-1213.3%-91.6%-26805.6%—

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$170.0M$133.0M$105.0M$210.0M$131.0M
Total Liabilities$259.0M$274.0M$267.0M$23.0M$21.0M
Cash$161.0M$103.0M$54.0M$40.0M$27.0M
Borrowings$2.0M$19.0M$17.0M$14.0M$11.0M

Latest News

Is Artiva Biotherapeutics, Inc. (ARTV) Outperforming Other Medical Stocks This Year? Zacks · Jul 8, 2026 Artiva Biotherapeutics to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference GlobeNewswire · Jun 23, 2026 Artiva Biotherapeutics Reports Positive AlloNK Data Across Autoimmune Diseases at EULAR 2026 MT Newswires · Jun 8, 2026 Artiva Biotherapeutics Highlights AlloNK® Data Presented at EULAR 2026, FDA RMAT Designation in Refractory Rheumatoid Arthritis and Webcast Today GlobeNewswire · Jun 8, 2026 Artiva Biotherapeutics to Participate in the 2026 Jefferies Global Healthcare Conference GlobeNewswire · May 28, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-15.0M$-51.0M$-47.0M$-55.0M$-77.0M
Investing Cash Flow$-3.0M$-13.0M$-29.0M$-121.0M$61.0M
Financing Cash Flow$-2.0M$-1.0M$24.0M$-4.0M$0
Net Cash Flow$136.0M$-58.0M$-49.0M$-13.0M$-13.0M
Free Cash Flow$-17.0M$-57.0M$-51.0M$-56.0M$-79.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA—
FCF Yield-41.22%
Quick Ratio8.16
Interest Coverage—
Return 1Y215.58%
Return 3Y—
Return 5Y—

Ownership

Insiders Held14.14%
Institutions Held51.58%
Institutions Float Held60.07%
Institutional HolderSharesReport Date
RA Capital Management, L.P.9,853,3022026-03-31
5AM Venture Management, LLC2,353,3042026-03-31
Venrock Adviser, LLC1,609,5692026-03-31
venBio Partners LLC531,3372026-03-31
Franklin Resources, Inc.520,3272026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ADVMAdverum Biotechnologies, Inc. $4.36 +0.00% -0.66 $96.26M 0.00%
ALXO $1.95 -2.26% -1.04 $261.72M 0.00%
CNTB $2.07 -1.67% -2.31 $130.02M 0.00%
DTIL $7.00 +1.60% -1.97 $89.80M 0.00%
GUTS $0.80 +3.62% -0.40 $57.83M 0.00%

About ARTV

ARTV is led by CEO Fred Aslan, employs 96 people, headquartered in US, publicly traded since 2024.

ARTV stock trades at $11.27 with a market capitalization of $278.56M. The stock is valued at a price-to-earnings (P/E) ratio of -2.29, price-to-book of 1.77, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $1.47 and $14.53, and currently trades 22.4% below its 52-week high.

On profitability, ARTV generates a return on equity (ROE) of -76.36%, return on capital employed of -82.73%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides